BACKGROUND: The relentless evolution of K. pneumoniae ST307 into a "superbug" with dual resistance to last-line antibiotics and hospital disinfectants poses an existential threat to infection control. This study characterizes the molecular epidemiology, resistance profiles, and biocide tolerance of ST307 isolates from Iranian hospitals, highlighting its role in nosocomial outbreaks. METHODS: A multicenter cross-sectional analysis of 500 K. pneumoniae isolates (2022-2024) utilized CLSI-compliant disk diffusion, broth microdilution, and PCR for resistance genes (bla(CTX-M-15), bla(NDM-1,)cepA, qacED1). Biocide MICs were correlated with genetic markers. RESULTS: ST307 accounted for 30% (150/500) of isolates, predominantly from ICUs. Resistance rates included meropenem (60.0%; MICâ â >32 µg/mL), ciprofloxacin (75.3%), and gentamicin (45.3%). Colistin retained efficacy (85.3% susceptibility). Elevated biocide MICs (chlorhexidineââ¥â0.5% [70.0%]; benzalkonium chlorideââ¥â0.1% [65.3%]) correlated with cepA (65.3%) and qacED1 (70.0%) positivity (pâ<â0.01). Carbapenemase genes bla(OXA-48) (22.0%) and bla(NDM-1) (10.0%) co-occurred with ESBLs. CONCLUSIONS: ST307's convergence of resistance mechanisms represents a catastrophic failure of current infection control frameworks. Without immediate interventions-such as ICU closures for deep disinfection, restricted colistin/tigecycline use, and genomic surveillance mandates-this clone will dominate Iranian hospitals within 3-5 years.
Convergence of multidrug resistance and efflux-mediated biocide tolerance in klebsiella pneumoniae ST307: implications for nosocomial infection control in Iranian hospitals.
阅读:12
作者:Goodarzi Rezvan, Kazemi Sima, Nasershariati Mohammad Hossein, Asghari Babak
| 期刊: | BMC Infectious Diseases | 影响因子: | 3.000 |
| 时间: | 2025 | 起止号: | 2025 Jun 3; 25(1):790 |
| doi: | 10.1186/s12879-025-11178-w | ||
特别声明
1、本文转载旨在传播信息,不代表本网站观点,亦不对其内容的真实性承担责任。
2、其他媒体、网站或个人若从本网站转载使用,必须保留本网站注明的“来源”,并自行承担包括版权在内的相关法律责任。
3、如作者不希望本文被转载,或需洽谈转载稿费等事宜,请及时与本网站联系。
4、此外,如需投稿,也可通过邮箱info@biocloudy.com与我们取得联系。
